Opko健康 OPK 深 沪
等待开盘 09-18 09:30:00 美东时间
1.39
0.000
0.00%
华盛通- 最 高1.43
- 今 开1.38
- 成交量 232.40万股
- 最 低 1.3745
- 昨 收 1.39
- 总市值 11.04亿
- 52周最高 2.035
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 1.11
- 委 比 67.62%
- 总股本 7.94亿
- 历史最高 19.20
- 量 比 1.25
- 振 幅 3.99%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Opko Health Sells BioReference Assets to Labcorp
Opko Health ( ($OPK) ) just unveiled an update. On September 15, 2025, OPKO Hea...
09-16 04:38
Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 TherapyOral GLP-2 Tablet Could Transform Treatment
09-15 21:05
Opko Health shares are trading lower after the company reported worse-than-expected Q2 sales results.
Opko Health shares are trading lower after the company reported worse-than-expe...
08-02 00:48
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
OPKO Health reported Q2 2025 business highlights and financial results. Key achievements include advancing the Merck Epstein-Barr virus vaccine trial, progressing immuno-oncology candidates MDX2001 and MDX2004, presenting promising data for OPK-88006 in metabolic dysfunction-associated steatohepatitis (MASH), and receiving FDA approval for the 4Kscore® Test without digital rectal examination information. The company also authorized an additional ...
07-31 20:05
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
OPKO Health, Inc. (NASDAQ: OPK) plans to release its Q2 and H1 2025 financial results after U.S. markets close on July 31, 2025. Management will host a conference call and live webcast at 4:30 p.m. ET on the same day. Participants can pre-register via a link to receive a unique access PIN or join by dialing 833-630-0584 (U.S.) or 412-317-1815 (Intl.). A webcast will also be available on OPKO’s Investor Relations page. A replay will be accessible ...
07-24 20:05
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health 和 Entera Bio 宣布，他们关于短肠综合征治疗的新型口服 GLP-2 类似物的研究摘要，被选中在 2025 年欧洲临床营养与代谢学会年会上展示。该疗法结合了 OPKO 的长效 GLP-2 激动剂和 Entera 的 N-Tab™ 技术，为短肠综合征患者提供更便捷的口服选择，目前唯一获批的 GLP-2 激动剂需每日注射。摘要强调了口服形式的潜在优势，如提高患者依从性及个性化治疗的可能。短肠综合征是一种罕见、可能危及生命的吸收障碍性疾病，影响约 3 万名美国和欧盟患者，市场规模庞大。OPKO 和 Entera 的合作旨在通过创新技术改善这类患者的治疗方案。
07-08 12:00
OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting
OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected
06-25 20:12
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
OPKO Health, Inc. (Nasdaq: OPK) announced its participation in the 3rd Annual Piper Sandler Obesity Symposium on June 26, 2025. Management will join a fireside discussion moderated by Edward Tentoff. Investors can register by contacting their Piper Sandler representative. OPKO is a biopharmaceutical and diagnostics company focused on large, rapidly growing markets.
06-25 15:00
